Biologix Hair Inc. Announces Opening of Corporate

Biologix Hair Inc. Announces Opening of Corporate Communications
Center in Halifax, Appoints Janice Matthews as VP Corporate
TORONTO, ONTARIO -- (Marketwire) -- 01/22/13 -- Biologix Hair Inc.
(OTCBB:TGPO) (OTCQB:TGPO) has announced the opening of its Corporate
Communications center in Halifax, Nova Scotia to lead the development
and dissemination of Biologix marketing and related materials. The
center will also serve as an in-house frontline point of contact for
general inquiries about the Company and the Biologix Hair Therapy
System(TM) as well as corporate questions from investors and
shareholders. Those with clinician licensing questions are encouraged
to contact the Clinician Licensing department in Toronto directly.  
The Corporate Communications center will be located in the heart of
the city in the Purdy's Wharf office complex, a high tech center with
modern conveniences with a reliable, stable communications
infrastructure. The area has a surplus of high quality talent
available at lower labor costs as compared to other areas and
Biologix has contracted with an international employee development
group to train local staff. As an added benefit, Halifax lies within
the Atlantic time zone (an hour ahead of Eastern), which helps bridge
the time difference between Europe and North America, allowing for
more efficient communication across the regions.  
Janice Matthews has been appointed Vice President of Corporate
Communications and will head up the center. Janice brings nearly
three decades of experience in communications with a wide variety of
clients from around the world. Ms. Matthews said, "I am excited about
working with such a talented, forward-looking group of people in this
cutting-edge opportunity and intend to put my experience and skills
to work immediately to contribute value to the Biologix team. The
Communication Center's placement in beautiful Halifax is certainly an
added bonus for me."  
Ron Holland, Biologix Chairman and CEO, stated, "Janice has strong
experience in creating clear marketing and related materials and
brings a skill set that will be of real benefit to Biologix as we
continue to expand. We are pleased to have her head up our Halifax
Communications center." 
About Biologix Hair Inc. and Biologix Hair Science Ltd.  
Biologix Hair Inc. (Biologix Hair), together with its wholly owned
biotechnology subsidiary, Biologix Hair Science Ltd. (TM) (BHS), is
focused on realizing the full market potential for its patent-pending
hair loss formula - Biologix Revive - and its demonstrated ability to
prevent and reverse the effects of alopecia, which plagues hundreds
of millions worldwide.  
Between mid-2004 and mid-2012, more than 30,000 pre-clinical-trial
treatments of Biologix Revive were administered to 5,000-plus
patients in South America suffering with varying degrees of alopecia,
as well as people seeking preventive treatment. The participating
treatment clinicians subjectively observed and reported that
virtually 100% of preventive care clients continued to retain their
healthy hair and an estimated 80-85% of the males and 90-plus% of the
females treated for hair regeneration experienced significant
regrowth of their own natural hair. And among alopecia areata
patients, virtually total hair regrowth was observed in 100% of the
cases. To date, no negative side effects have been reported.  
BHS is currently focused on obtaining FDA approval for its
breakthrough hair loss prevention and regeneration therapy and has
initiated a research and development program with one of the world's
leading medical research universities, the Beijing Institute of
Technology (BIT). The R&D program, expected to take approximately
twelve months to complete, is an important final step before formal
clinical trials and the FDA approval process begins.  
Additionally, on May 11, 2012, Venable LLC, the Washington-based law
firm overseeing the worldwide IP and regulatory approval processes on
behalf of BHS, filed a Patent Cooperation Treaty (PCT) application on
behalf of BHS for Biologix Revive in Geneva, Switzerland. The PCT is
an international treaty, administered by the World Intellectual
Property Organization (WIPO), to which 144 countries have as of now
contracted, including Canada and the United States.  
Biologix management is determined to be in a ready position to
capitalize on the high-margin sales potential of the Biologix Hair
Therapy System(TM), if and when FDA and other major market approvals
are forthcoming.  
As BHS advances the regulatory approval process, Biologix Hair,
together with wholly owned subsidiary companies operated by BHS, are
rapidly developing a global distribution network of licensed
clinicians and medical practitioners seeking to become Certified
Biologix Hair Therapists(TM) and secure exclusive territorial
purchasing and treatment rights for the Biologix Hair Therapy
Biologix Hair has decided not to risk creating any potential
regulatory conflicts by offering treatment outside the United States
and other major high-product-margin markets until FDA approval has
been granted. Therefore, the Biologix Hair Therapy System(TM) is not
yet available other than to the 5,000+ patients who participated in
the pre-clinical-trials conducted in South America.  
To learn more about Clinician Licensing opportunities, Click Here or
call toll free +1 855.737.0333 or +1 647.344.5900. 
This announcement is not an offer to sell any Biologix Hair Inc.
("Biologix") securities. Offers for any given security are made only
through applicable offering circulars and related documents filed
with the SEC pursuant to the Securities Act of 1933 or the Securities
Exchange Act of 1934. Certain statements contained herein and
subsequent oral statements made by and on behalf of Biologix may
contain "forward-looking statements". Such forward-looking statements
are identified by words such as "intends," "anticipates," "believes,"
"expects" and "hopes" and includes, without limitation, the
development of treatment centers and approval from regulatory
authorities. Forward-looking statements express our expectations or
predictions of future events or results. They are not guarantees and
are subject to many risks and uncertainties. There are a number of
factors beyond our control that could cause actual events or results
to be significantly different from those described in the
forward-looking statements. Any or all of our forward-looking
statements in this report or in any other public statements we make
may turn out to be wrong. We undertake no obligation to publicly
update or review any forward-looking statements, whether as a result
of new information, future developments or otherwise. In Canada,
Europe and the United States, the Biologix treatment is not approved
for use by Health Canada, EMA or the FDA. The company makes no
representations that it will receive Health Canada, EMA or FDA
Biologix Hair Inc.
Corporate Communications
+1 902.801.7920 or Toll Free: +1 855.292.8585
Press spacebar to pause and continue. Press esc to stop.